{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:04:28Z","timestamp":1794744268204,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1\\u2013029"],"award-info":[{"award-number":["2021-I2M-1\\u2013029"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neuropharm.2025.110788","type":"journal-article","created":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T23:00:42Z","timestamp":1764543642000},"page":"110788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Analgesic effect of cinobufagin is mediated by human-selective P2X7R antagonism governed by distinct extracellular domains"],"prefix":"10.1016","volume":"285","author":[{"given":"Kexin","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-990X","authenticated-orcid":false,"given":"Haibo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110788_bib1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1126\/science.1156916","article-title":"The cell and molecular basis of mechanical, cold, and inflammatory pain","volume":"321","author":"Abrahamsen","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2025.110788_bib2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1124\/mol.117.111021","article-title":"Mapping the allosteric action of antagonists A740003 and A438079 reveals a role for the left flipper in ligand sensitivity at P2X7 receptors","volume":"93","author":"Allsopp","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110788_bib3","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41598-017-00732-5","article-title":"Unique residues in the ATP gated human P2X7 receptor define a novel allosteric binding pocket for the selective antagonist AZ10606120","volume":"7","author":"Allsopp","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110788_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12974-019-1616-z","article-title":"The spinal microglial IL-10\/\u03b2-endorphin pathway accounts for cinobufagin-induced mechanical antiallodynia in bone cancer pain following activation of \u03b17-nicotinic acetylcholine receptors","volume":"17","author":"Apryani","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110788_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awaf044","article-title":"Novel insight into TRPV1-induced mitochondrial dysfunction in neuropathic pain","author":"Awad-Igbaria","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2025.110788_bib6","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/glia.23001","article-title":"The microglial ATP-gated ion channel P2X7 as a CNS drug target","volume":"64","author":"Bhattacharya","year":"2016","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2025.110788_bib7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1124\/mol.119.116715","article-title":"Mapping the site of action of human P2X7 receptor antagonists AZ11645373, brilliant blue G, KN-62, calmidazolium, and ZINC58368839 to the intersubunit allosteric pocket","volume":"96","author":"Bin Dayel","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110788_bib8","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1007\/s00210-025-03902-9","article-title":"Cinobufagin: unveiling the hidden bufadienolide's promise in combating alimentary canal cancer development and progression - a comprehensive review","volume":"398","author":"Boaro","year":"2025","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.neuropharm.2025.110788_bib9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/jm049363q","article-title":"Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors","volume":"48","author":"Bodnar","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110788_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/851256","article-title":"A study on the mechanism of cinobufagin in the treatment of paw cancer pain by modulating local \u03b2 -Endorphin expression in vivo","volume":"2013","author":"Chen","year":"2013","journal-title":"Evid. Based Complement Alternat. Med."},{"key":"10.1016\/j.neuropharm.2025.110788_bib11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pain.2005.01.002","article-title":"Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain","volume":"114","author":"Chessell","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2025.110788_bib12","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2025.110788_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/biom12091309","article-title":"6-Furopyridine hexamethylene amiloride is a non-selective P2X7 receptor antagonist","volume":"12","author":"Cuthbertson","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuropharm.2025.110788_bib14","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2147\/JIR.S351660","article-title":"ATP-activated P2X7R promote the attack of acute gouty arthritis in rats through activating NLRP3 inflammasome and inflammatory cytokine production","volume":"15","author":"Dai","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.neuropharm.2025.110788_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13461","article-title":"Bone marrow-derived mesenchymal stem cells attenuate complete Freund's adjuvant-induced inflammatory pain by inhibiting the expression of P2X3","volume":"56","author":"Deng","year":"2023","journal-title":"Cell Prolif."},{"key":"10.1016\/j.neuropharm.2025.110788_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.tins.2015.02.001","article-title":"Epigenetic mechanisms of chronic pain","volume":"38","author":"Descalzi","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110788_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","article-title":"The P2X7 receptor in infection and inflammation","volume":"47","author":"Di Virgilio","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.neuropharm.2025.110788_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.tcb.2018.01.005","article-title":"The elusive P2X7 macropore","volume":"28","author":"Di Virgilio","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.neuropharm.2025.110788_bib19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/bja\/aen107","article-title":"Neuropathic pain: emerging treatments","volume":"101","author":"Dray","year":"2008","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2025.110788_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2017.00123","article-title":"The P2X7 Receptor-Interleukin-1 liaison","volume":"8","author":"Giuliani","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110788_bib21","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1111\/bph.13123","article-title":"Selected ginsenosides of the protopanaxdiol series are novel positive allosteric modulators of P2X7 receptors","volume":"172","author":"Helliwell","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110788_bib22","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1124\/jpet.106.111559","article-title":"A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat","volume":"319","author":"Honore","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110788_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108233","article-title":"Hyperactivity of innate immunity triggers pain via TLR2-IL-33-Mediated neuroimmune crosstalk","volume":"33","author":"Huang","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2025.110788_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21175996","article-title":"P2X7 receptors amplify CNS damage in neurodegenerative diseases","volume":"21","author":"Illes","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110788_bib25","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.22153","article-title":"Structural basis for subtype-specific inhibition of the P2X7 receptor","volume":"5","author":"Karasawa","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.neuropharm.2025.110788_bib26","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31186","article-title":"The P2X7 receptor forms a dye-permeable pore independent of its intracellular domain but dependent on membrane lipid composition","volume":"6","author":"Karasawa","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.neuropharm.2025.110788_bib27","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/annrheumdis-2011-143578","article-title":"Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine","volume":"71","author":"Keystone","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.neuropharm.2025.110788_bib28","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1111\/bph.13262","article-title":"\u03b4 subunit-containing GABAA receptors are preferred targets for the centrally acting analgesic flupirtine","volume":"172","author":"Klinger","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110788_bib29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.cell.2019.09.017","article-title":"Full-length P2X(7) structures reveal how palmitoylation prevents channel desensitization","volume":"179","author":"McCarthy","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2025.110788_bib30","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/bjp.2008.306","article-title":"Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects","volume":"155","author":"Michel","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110788_bib31","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1476-5381.2009.00135.x","article-title":"Mechanism of action of species-selective P2X(7) receptor antagonists","volume":"156","author":"Michel","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110788_bib32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14728222.2024.2416961","article-title":"Targeting the TRPV1 pain pathway in osteoarthritis of the knee","volume":"28","author":"Mobasheri","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neuropharm.2025.110788_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3389\/fphys.2020.00473","article-title":"Peripheral inflammatory hyperalgesia depends on P2X7 receptors in satellite glial cells","volume":"11","author":"Neves","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.neuropharm.2025.110788_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado5084","article-title":"P2X(7) receptors exhibit at least three modes of allosteric antagonism","volume":"10","author":"Oken","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.neuropharm.2025.110788_bib35","doi-asserted-by":"crossref","first-page":"8283","DOI":"10.1038\/s41467-025-62643-8","article-title":"A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor","volume":"16","author":"Oken","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2025.110788_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106736","article-title":"Silent agonists for \u03b17 nicotinic acetylcholine receptors","volume":"190","author":"Papke","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2025.110788_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/13543776.2017.1246538","article-title":"P2X7 receptor antagonists: a patent review (2010-2015)","volume":"27","author":"Park","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neuropharm.2025.110788_bib38","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1021\/jm500324g","article-title":"Discovery of novel 2,5-dioxoimidazolidine-based P2X(7) receptor antagonists as constrained analogues of KN62","volume":"58","author":"Park","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110788_bib39","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1038\/sj.emboj.7601378","article-title":"Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor","volume":"25","author":"Pelegrin","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.neuropharm.2025.110788_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107609","article-title":"How spinal GABAergic circuits modulate cerebral processing of postsurgical pain","volume":"212","author":"Pradier","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2025.110788_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117157","article-title":"Irisin alleviates CFA-induced inflammatory pain by modulating macrophage polarization and spinal glial cell activation","volume":"178","author":"Rahman","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2025.110788_bib42","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/emboj\/20.10.2349","article-title":"Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel","volume":"20","author":"Saegusa","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.neuropharm.2025.110788_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/5584_2017_59","article-title":"The P2X7 receptor","volume":"1051","author":"Sluyter","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2025.110788_bib44","article-title":"Deep-insights: nanoengineered gel-based localized drug delivery for arthritis management","volume":"20","author":"Sriram","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2025.110788_bib45","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3899\/jrheum.110874","article-title":"Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate","volume":"39","author":"Stock","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.neuropharm.2025.110788_bib46","article-title":"C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models","volume":"135","author":"Tang","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neuropharm.2025.110788_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1744-8069-10-37","article-title":"Gain and loss of function of P2X7 receptors: mechanisms, pharmacology and relevance to diabetic neuropathic pain","volume":"10","author":"Ursu","year":"2014","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2025.110788_bib48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1021\/acschemneuro.8b00369","article-title":"Alpha-7 nicotinic receptor-targeted cinobufagin induces antinociception and inhibits NF-\u03baB signaling pathway in DRG neurons","volume":"10","author":"Xu","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110788_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108476","article-title":"Immunotherapies in chronic pain through modulation of neuroimmune interactions","volume":"248","author":"Zhao","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2025.110788_bib50","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.2147\/JIR.S421548","article-title":"Suppression of P2X7R by local treatment alleviates acute gouty inflammation","volume":"16","author":"Zhao","year":"2023","journal-title":"J. Inflamm. Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:30:33Z","timestamp":1781771433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825004964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":50,"alternative-id":["S0028390825004964"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110788","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analgesic effect of cinobufagin is mediated by human-selective P2X7R antagonism governed by distinct extracellular domains","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110788"}}